17-Hydroxypregnenolone, MS (female)

This test serves as a valuable ancillary tool in diagnosing congenital adrenal hyperplasia (CAH), especially in cases where 21-hydroxylase and 11-hydroxylase deficiencies have already been ruled out. It is particularly instrumental in confirming a diagnosis of 3-beta-hydroxydehydrogenase (3-b-HSD) deficiency and 17-alphahydroxylase deficiency. Additionally, it is an essential component of a comprehensive battery of tests used to assess females experiencing hirsutism or infertility, both of which can be potential outcomes of adult-onset CAH.

17-Hydroxypregnenolone is a steroid hormone produced within the body. The measurement of its levels in the blood serum provides valuable insights into hormonal balance and endocrine function. 

Deviations from the normal range of 17-Hydroxypregnenolone levels can indicate various medical conditions, including congenital adrenal hyperplasia and other hormonal disorders. 

What is Congenital Adrenal Hyperplasia?

Congenital adrenal hyperplasia (CAH) is a term used to describe a group of genetic disorders that impact the adrenal glands, which are small, walnut-sized organs located above the kidneys. These adrenal glands play a crucial role in producing several important hormones, including:

Cortisol: This hormone regulates the body's response to illness or stress.

Mineralocorticoids, such as aldosterone: These hormones are responsible for regulating sodium and potassium levels in the body.

Androgens, including testosterone: These are male sex hormones that are essential for growth and development in both males and females.

Individuals with CAH have a genetic mutation that leads to a deficiency in one of the enzymes necessary for the production of these hormones. There are two primary types of congenital adrenal hyperplasia:

1. Classic CAH: This is a rarer and more severe form of the condition, typically detected at birth or in early infancy.
2. Non-classic CAH: This form is milder and more common, often not identified until childhood or early adulthood.

While there is no cure for CAH, proper treatment can effectively manage the condition. With appropriate medical care and hormone replacement therapy, most individuals with CAH can lead full and healthy lives.

Reference Ranges:

Premature (26 to 28 weeks): day 4: 375−3559 ng/dL

Premature (31 to 35 weeks): day 4: 64−2380 ng/dL

3 days: 10−829 ng/dL

1 to 5 months: 36−763 ng/dL

6 to 11 months: 42−540 ng/dL

12 to 23 months: 14−207 ng/dL

24 months to 5 years: 10−103 ng/dL

6 to 9 years: 10−186 ng/dL

Pubertal: 44−235 ng/dL

Adults: 53−357 ng/dL